San Francisco, October 31, 2023 – Ikonisys SA a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, has partnered with Biocare Medical, a leader in immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) tools and reagents. This alliance focuses on expanding the global distribution of the low volume Ikoniscope20 and high volume Ikoniscope20max, the fully automated instruments for FISH slides analysis manufactured by Ikonisys.
Biocare Medical’s recent acquisition of Empire Genomics has expanded their offering to include over 1 million FISH probes. With this significant augmentation in their FISH probe library, a collaboration with Ikonisys, which provides an advanced fluorescence microscope, becomes even more strategic.
Mario Crovetto, Ikonisys’ CEO, comments, “This collaboration is a definitive move in our commercial strategy. Leveraging Biocare Medical’s expanded FISH capabilities and commercial excellence and acumen, with our Ikoniscope platform will reshape the diagnostic landscape. Thanks to this strategic alliance, together with ongoing commercial developments, we have greatly expanded our visibility over the next 2 years and expect to reach annual revenues between €5 and €7 million by this time”
Biocare Medical stands out with a comprehensive portfolio encompassing IHC, molecular reagents, tissue-conserving multiplex solutions, and a suite of advanced instruments across clinical, research, and biopharma sectors.
Luis de Luzuriaga, CEO of Biocare Medical, states, “Our portfolio of Empire Genomics probes offers clinicians the broadest menu on the market today. Partnering with Ikonisys and integrating their diagnostic tools with our molecular offerings will enable laboratories to achieve a turnkey solution for fluorescence digital pathology.”
The collaboration between Ikonisys and Biocare Medical aims to provide an all-encompassing solution, merging an unlimited menu of clinical and research FISH probes with fluorescent slide digitization and analysis via the Ikoniscope platform. This partnership’s objective is to broaden the reach of innovative technologies, equipping healthcare professionals with more refined diagnostic tools in regions including the U.S., Europe, and most of Asia-Pacific.
By leveraging Biocare Medical’s distribution channels, which span over 4,000 global laboratories, Ikonisys can direct its resources on expanding its product portfolio.